1. Kim KS, Park SW, Cho YW, Kim SK. 2018;Higher prevalence and progression rate of chronic kidney disease in elderly patients with type 2 diabetes mellitus.
Diabetes Metab J 42:224–232.
2. Bae JC. 2018;Trends of diabetes epidemic in Korea.
Diabetes Metab J 42:377–379.
3. Kim KJ, Kwon TY, Yu S, et al. 2018;Ten-year mortality trends for adults with and without diabetes mellitus in South Korea, 2003 to 2013.
Diabetes Metab J 42:394–401.
4. Kim BY, Won JC, Lee JH, et al. 2019;Diabetes fact sheets in Korea, 2018: an appraisal of current status.
Diabetes Metab J 43:487–494.
5. Inker LA, Astor BC, Fox CH, et al. 2014;KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.
Am J Kidney Dis 63:713–735.
6. Clemens KK, Liu K, Shariff S, Schernthaner G, Tangri N, Garg AX. 2016;Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.
Diabetes Obes Metab 18:607–614.
7. Hung SC, Chang YK, Liu JS, et al. 2015;Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study.
Lancet Diabetes Endocrinol 3:605–614.
8. American Diabetes Association. 2019;9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019.
Diabetes Care 42(Suppl 1):S90–S102.
9. U.S. Food and Drug Administration. c2017 FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function [Internet] U.S. Food and Drug Administration; Silver Spring (US): Available from:
http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. cited 2020 Jan 28.
10. Packer M. 2018;Is metformin beneficial for heart failure in patients with type 2 diabetes?
Diabetes Res Clin Pract 136:168–170.
11. Aharaz A, Pottegård A, Henriksen DP, Hallas J, Beck-Nielsen H, Lassen AT. 2018;Risk of lactic acidosis in type 2 diabetes patients using metformin: a case control study.
PLoS One 13:e0196122.
12. Lee EY, Hwang S, Lee YH, et al. 2017;Association between Metformin use and risk of Lactic acidosis or elevated lactate concentration in type 2 diabetes.
Yonsei Med J 58:312–318.
13. Tseng CH. 2019;Metformin use is associated with a lower risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: a retrospective cohort analysis.
J Am Heart Assoc 8:e011640.
14. Chan NN, Brain HP, Feher MD. 1999;Metformin-associated lactic acidosis: a rare or very rare clinical entity?
Diabet Med 16:273–281.
15. Oates NS, Shah RR, Idle JR, Smith RL. 1983;Influence of oxidation polymorphism on phenformin kinetics and dynamics.
Clin Pharmacol Ther 34:827–834.
16. Richy FF, Sabidó-Espin M, Guedes S, Corvino FA, Gottwald-Hostalek U. 2014;Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study.
Diabetes Care 37:2291–2295.
17. Luft D, Schmülling RM, Eggstein M. 1978;Lactic acidosis in biguanide-treated diabetics: a review of 330 cases.
Diabetologia 14:75–87.
18. Lalau JD. 2010;Lactic acidosis induced by metformin: incidence, management and prevention.
Drug Saf 33:727–740.
19. Lalau JD, Kajbaf F, Protti A, Christensen MM, De Broe ME, Wiernsperger N. 2017;Metformin-associated lactic acidosis (MALA): moving towards a new paradigm.
Diabetes Obes Metab 19:1502–1512.
21. Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME. 2018;Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4.
Diabetes Care 41:547–553.
22. Kim MK, Ko SH, Kim BY, et al. Committee of Clinical Practice Guidelines, Korean Diabetes Association. 2019;2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea.
Diabetes Metab J 43:398–406.
23. Herts BR, Schneider E, Poggio ED, Obuchowski NA, Baker ME. 2008;Identifying outpatients with renal insufficiency before contrast-enhanced CT by using estimated glomerular filtration rates versus serum creatinine levels.
Radiology 248:106–113.
24. Davenport MS, Khalatbari S, Cohan RH, Ellis JH. 2013;Contrast medium-induced nephrotoxicity risk assessment in adult inpatients: a comparison of serum creatinine level- and estimated glomerular filtration rate-based screening methods.
Radiology 269:92–100.
25. Choyke PL, Cady J, DePollar SL, Austin H. 1998;Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients?
Tech Urol 4:65–69.
26. Tippins RB, Torres WE, Baumgartner BR, Baumgarten DA. 2000;Are screening serum creatinine levels necessary prior to outpatient CT examinations?
Radiology 216:481–484.
27. Baumgarten DA, Ellis JH. 2008;Contrast-induced nephropathy: contrast material not required?
AJR Am J Roentgenol 191:383–386.
28. Davenport MS, Cohan RH, Khalatbari S, Ellis JH. 2014;The challenges in assessing contrast-induced nephropathy: where are we now?
AJR Am J Roentgenol 202:784–789.
29. Ellis JH, Cohan RH. 2009;Reducing the risk of contrast-induced nephropathy: a perspective on the controversies.
AJR Am J Roentgenol 192:1544–1549.
30. Katzberg RW, Newhouse JH. 2010;Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe?
Radiology 256:21–28.
31. McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE. 2014;Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate.
Radiology 271:65–73.
32. Newhouse JH, RoyChoudhury A. 2013;Quantitating contrast medium-induced nephropathy: controlling the controls.
Radiology 267:4–8.
33. Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. 2005;Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro.
Radiology 235:843–849.
34. Sendeski M, Patzak A, Pallone TL, Cao C, Persson AE, Persson PB. 2009;Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy.
Radiology 251:697–704.
35. Haight AE, Kaste SC, Goloubeva OG, Xiong XP, Bowman LC. 2003;Nephrotoxicity of iopamidol in pediatric, adolescent, and young adult patients who have undergone allogeneic bone marrow transplantation.
Radiology 226:399–404.
36. Senthilnathan S, Gauvreau K, Marshall AC, Lock JE, Bergersen L. 2009;Contrast administration in pediatric cardiac catheterization: dose and adverse events.
Catheter Cardiovasc Interv 73:814–820.
38. Shah AD, McHargue C, Yee J, Rushakoff RJ. 2016;Intravenous contrast in patients with diabetes on metformin: new common sense guidelines.
Endocr Pract 22:502–505.
39. Goergen SK, Rumbold G, Compton G, Harris C. 2010;Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrast medium for patients receiving metformin.
Radiology 254:261–269.
42. Han S, Yoon SH, Lee W, Choi YH, Kang DY, Kang HR. 2019;Management of adverse reactions to iodinated contrast media for computed tomography in Korean referral hospitals: a survey investigation.
Korean J Radiol 20:148–157.
43. Corremans R, Vervaet BA, D'Haese PC, Neven E, Verhulst A. 2018;Metformin: a candidate drug for renal diseases.
Int J Mol Sci 20:E42
44. Korea Ministry of Food and Drug Safety. c2018 Instructions on the change of permit for metformin hydrochloride (tablet) (uniform adjustment) [Internet] Ministry of Food and Drug Safety; Cheongju (Korea): Available from:
https://nedrug.mfds.go.kr/bbs/58/2683/. cited 2018 Jan 3.